Copyright
©The Author(s) 2017.
World J Gastrointest Pharmacol Ther. Feb 6, 2017; 8(1): 39-46
Published online Feb 6, 2017. doi: 10.4292/wjgpt.v8.i1.39
Published online Feb 6, 2017. doi: 10.4292/wjgpt.v8.i1.39
S# | Name | Indication | Limitations | Sensitivity | Specificity |
Biomarkers of IBD | |||||
1 | Calprotectin | Distinguishing functional from organic bowel disease and predicting relapse in IBD | Disease nonspecific Affected by age, comorbidities, NSAIDs use Day to day variations Miss low level inflammatory activity | 70%-100% | 70%-100% |
2 | S100 proteins | Inflammatory marker for IBD | 60%-67% | 70%-90% | |
3 | Lactoferrin | Markers of inflammation, Distinguish between IBS and IBD | Nonspecific marker of inflammation Raised in breastfeeding infants Cannot predict low level inflammation | 67%-87% | 90%-100% |
Biomarker of cell turnover | |||||
4 | M2-PK | Screening of gastrointestinal tract cancers | Also raised in inflammation | 67%-93% | 88%-92% |
Biomarkers of digestion and malabsorption | |||||
5 | Elastase-1 (e1) | Pancreatic insufficiency | Low specificity, also affected by other intestinal disorders | 100% | 96% |
6 | Fecal fat | Liver damage, hypolipidemic drugs, impaired gallbladder function, Celiac disease, Small bowel bacterial overgrowth | Cannot predict severity of disease Cannot be performed in diarrhea Not accurate or specific test | 70%-94% | 80%-99% |
7 | Α1-antitrypsin | Protein-Losing Enteropathy, Whipple lipodystrophy, gastric carcinoma, intestinal lymphangiectasia | Nonspecific marker. Levels affected by inflammation | 60%-78% | 80%-85% |
S# | Name | Source | Function | Indication | Limitations |
Biomarkers of inflammatory bowel disease | |||||
1 | Cathelicidins | Secreted by Neutrophils, keratinocytes and epithelial cells of gastrointestinal tract, respiratory tract, urogenital tract | Antibacterial activity, modulate inflammation by altering cytokine response, chemoattraction of inflammatory cells in diseased tissues | Marker of inflammation (IBD) and Shigellosis | Antimicrobial peptides so also increased in GI infections |
2 | Osteoprotegerin | Member of the TNF receptor superfamily | Binds to RANKL and blocks its interaction with RANK | Marker of inflammation (IBD) | Plays a role in bone metabolism so levels are increased in bone diseases |
3 | Beta-glucuronidase | Produced by colonocytes Also produced by anaerobic gut bacteria (particularly E. coli) | Enzyme that breaks down complex carbohydrates Deconjugate glucuronide molecules from a variety of toxins, carcinogens, hormones, and drugs | Marker of inflammation (IBD) | False results in cases of GI bacterial infection |
4 | Neutrophil Gelatinase Associated lipocalin | Member of the lipocalin family, secreted by neutrophils | Immunomodulation. Attaches to and neutralizes bacterial formylpepetides | Marker of inflammation (IBD) | Also increased in GI infections like enterocolitis |
Eosinophil related proteins | |||||
5 | Eosinophil Protein X | When lamina propria is damaged, eosinophils migrate into the gut lumen Released by eosinophil; contribute to ongoing inflammation and tissue destruction | Marker of Eosinophil activity, Allergic and Parasitic influences | IgE-mediated food allergy Intestinal parasitic infection IBD | Also increased in GI inflammation |
Biomarker of cell turnover | |||||
6 | Defensins | Expressed by neutrophils, epithelial and mucosal lining cell in small and large intestine | Antimicrobial peptide | Markers of colorectal cancer | Also raised in inflammation |
Biomarkers of gut health | |||||
7 | Fecal secretory IgA | Secreted from mucosal surfaces | Gut epithelial barrier; Defense against the entry of enteric toxins and pathogenic organisms Development of immune tolerance of normal commensal gut organisms | Evaluate immunological response to intestinal pathogens Colorectal cancer | Cannot be used in subjects with immunoglobulin deficiency |
8 | SCFAs | Products of fermentation by colonic microbial flora; common ones are propionate, acetate, and butyrate | Provides 60%-70% of colonocytes energy requirements Lower colonic pH | Marker of inflammation (IBD) | < 5% of SCFA produced is excreted in stool Also levels altered by diet and rate of transit |
- Citation: Siddiqui I, Majid H, Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J Gastrointest Pharmacol Ther 2017; 8(1): 39-46
- URL: https://www.wjgnet.com/2150-5349/full/v8/i1/39.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v8.i1.39